StockNews.AI
IRIX
StockNews.AI
5 hrs

Iridex Corporation Receives Formal Notification of Nasdaq Listing Compliance

1. IRIDEX regained Nasdaq compliance with stockholders' equity requirements. 2. Previously non-compliant due to issues reported in March 2025. 3. Compliant status confirmed by Nasdaq on August 27, 2025. 4. IRIDEX specializes in innovative laser treatments for eye conditions. 5. Products are sold globally through distributors in over 100 countries.

4m saved
Insight
Article

FAQ

Why Bullish?

Regaining compliance with Nasdaq typically increases investor confidence, historically leading to price upticks.

How important is it?

Regaining compliance signals operational stability, vital for investor interest and trust.

Why Short Term?

The immediate effects of compliance are likely to influence pricing within a quarter.

Related Companies

AXSMALNAHEAR
September 09, 2025 16:05 ET  | Source: IRIDEX Corporation MOUNTAIN VIEW, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced that it has received formal notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that Iridex has evidenced compliance with the continued listing requirements. As previously reported, on May 14, 2025, Iridex received a notification of non-compliance from Nasdaq’s Listing Qualifications Department notifying the Company that, based upon its quarterly report on Form 10-Q for the quarterly period ended March 29, 2025 that was filed with the Securities and Exchange Commission (the “SEC”) on May 13, 2025, the Company was not in compliance with the continued listing standards set forth in Nasdaq Listing Rule 5550(b). On August 27, 2025, the Company received formal notification from Nasdaq confirming that the Company had regained compliance with the continued listing standards of Nasdaq Listing Rule 5550(b) by satisfying the minimum stockholders’ equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(1) based upon its quarterly report on Form 10-Q for the quarterly period ended June 28, 2025 that was filed with the SEC on August 12, 2025. The matter is now closed.    About Iridex Corporation  Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com. MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions.  © 2025 Iridex Corporation.  All rights reserved. Investor Relations ContactPhilip TaylorGilmartin Groupinvestors@iridex.com

Related News